Advocated for funding to advance from basic research to clinical readiness a first generation stem cell medicine for muscle regeneration and traumatic brain injury by using the fundamental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Duration: January 1, 2009
to
September 30, 2012
General Issues: Medical/Disease Research/Clinical Labs , Budget/Appropriations , Defense , Veterans , Health Issues
Spending: about $270,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2009: House of Representatives, U.S. Senate, Defense Advanced Research Projects Agency (DARPA), Defense - Dept of (DOD), U.S. Senate,, Natl Institutes of Health (NIH), Veterans Affairs - Dept of (VA)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
3rd Quarter, 2012
PETRIZZO BOND, INC. terminated an engagement in which they represented Fate Therapeutics, Inc. on Oct. 2, 2012.
Original Filing: 300503620.xml
2nd Quarter, 2012
In Q2, PETRIZZO BOND, INC. did no lobbying for Fate Therapeutics, Inc. . The report was filed on July 10, 2012.
Original Filing: 300482028.xml
1st Quarter, 2012
In Q1, PETRIZZO BOND, INC. did no lobbying for Fate Therapeutics, Inc. . The report was filed on April 11, 2012.
Original Filing: 300459097.xml
4th Quarter, 2011
In Q4, PETRIZZO BOND, INC. (PETRIZZO STRATEGIC GROUP, INC.) lobbied for Fate Therapeutics, Inc. , earning $20,000. The report was filed on Jan. 10, 2012.
Original Filing: 300435573.xml
Lobbying Issues
Advocated for funding to advance from basic research to clinical readiness a first generation stem cell medicine for muscle regeneration and traumatic brain injury by using the fundamental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs Budget/Appropriations
Lobbying Issues
Advocated for funding to advance from basic research to clinical readiness a first generation stem cell medicine for muscle regeneration and traumatic brain injury by using the fundamental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Defense Advanced Research Projects Agency (DARPA) Defense - Dept of (DOD)
3rd Quarter, 2011
In Q3, PETRIZZO STRATEGIC GROUP, INC. lobbied for Fate Therapeutics, Inc. , earning $20,000. The report was filed on Oct. 12, 2011.
Original Filing: 300412526.xml
Lobbying Issues
Advocated for funding to advance from basic research to clinical readiness a first generation stem cell medicine for muscle regeneration by using the fundamental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocated for funding to advance from basic research to clinical readiness a first generation stem cell medicine for muscle regeneration and traumatic brain injury by using the fundamental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Advocated for funding to advance from basic research to clinical readiness a first generation stem cell medicine for muscle regeneration and traumatic brain injury by using the fundamental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Defense Advanced Research Projects Agency (DARPA) Defense - Dept of (DOD)
2nd Quarter, 2011
In Q2, PETRIZZO STRATEGIC GROUP, INC. lobbied for Fate Therapeutics, Inc. , earning $20,000. The report was filed on July 18, 2011.
Original Filing: 300394241.xml
Lobbying Issues
Advocated for funding to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocated for funding to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Advocated for funding to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Defense Advanced Research Projects Agency (DARPA)
1st Quarter, 2011
In Q1, PETRIZZO STRATEGIC GROUP, INC. lobbied for Fate Therapeutics, Inc. , earning $20,000. The report was filed on April 10, 2011.
Original Filing: 300361404.xml
Lobbying Issues
Advocated for funding to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight, and bone fractures by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocated for funding to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight, and bone fractures by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Advocated for funding to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight, and bone fractures by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Defense Advanced Research Projects Agency (DARPA)
4th Quarter, 2010
In Q4, PETRIZZO STRATEGIC GROUP, INC. lobbied for Fate Therapeutics, Inc. , earning $20,000. The report was filed on Jan. 12, 2011.
Original Filing: 300336718.xml
Lobbying Issues
Advocated for federal funding in the FY 2011 Defense Appropriations to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight, and bone fractures by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
3rd Quarter, 2010
In Q3, PETRIZZO STRATEGIC GROUP, INC. lobbied for Fate Therapeutics, Inc. , earning $25,000. The report was filed on Oct. 14, 2010.
Original Filing: 300313230.xml
Lobbying Issues
Advocated for federal funding in the FY 2011 Defense Appropriations to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight, and bone fractures by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
2nd Quarter, 2010
In Q2, PETRIZZO STRATEGIC GROUP, INC. lobbied for Fate Therapeutics, Inc. , earning $25,000. The report was filed on July 17, 2010.
Original Filing: 300290328.xml
Lobbying Issues
Advocated for federal funding in the FY 2011 Defense Appropriations to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight, and bone fractures by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
1st Quarter, 2010
In Q1, PETRIZZO STRATEGIC GROUP, INC. lobbied for Fate Therapeutics, Inc. , earning $20,000. The report was filed on April 18, 2010.
Original Filing: 300262272.xml
Lobbying Issues
Advocated for federal funding in the FY 2011 Defense Appropriations to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight, and bone fractures by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs Defense
Lobbying Issues
Advocated for federal funding in the FY 2011 Defense Appropriations to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight, and bone fractures by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2009
In Q4, PETRIZZO STRATEGIC GROUP, INC. lobbied for Fate Therapeutics, Inc. , earning $20,000. The report was filed on Jan. 14, 2010.
Original Filing: 300231688.xml
Lobbying Issues
Secured federal assistance to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight and bone fractures by using the fundamental biological mechanisms that guise cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
3rd Quarter, 2009
In Q3, PETRIZZO STRATEGIC GROUP, INC. lobbied for Fate Therapeutics, Inc. , earning $20,000. The report was filed on Oct. 17, 2009.
Original Filing: 300208737.xml
Lobbying Issues
Secured federal assistance to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight and bone fractures by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs Budget/Appropriations Defense Veterans
2nd Quarter, 2009
In Q2, PETRIZZO STRATEGIC GROUP, INC. lobbied for Fate Therapeutics, Inc. , earning $20,000. The report was filed on July 18, 2009.
Original Filing: 300185095.xml
Lobbying Issues
Secure federal assistance to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight and bone fractures by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and rug development focuses on modulating adult stem cell biology both in vivo to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institutes of Health (NIH) Defense - Dept of (DOD) Veterans Affairs - Dept of (VA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Secure federal assistance to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight and bone fractures by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and rug development focuses on modulating adult stem cell biology both in vivo to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Secure federal assistance to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight and bone fractures by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and rug development focuses on modulating adult stem cell biology both in vivo to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Defense - Dept of (DOD)
Lobbying Issues
Secure federal assistance to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight and bone fractures by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and rug development focuses on modulating adult stem cell biology both in vivo to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Veterans Affairs - Dept of (VA)
1st Quarter, 2009
In Q1, PETRIZZO STRATEGIC GROUP, INC. lobbied for Fate Therapeutics, Inc. , earning $20,000. The report was filed on April 14, 2009.
Original Filing: 300147188.xml
Lobbying Issues
Secure federal assistance to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight and bone fractures by using the fundamental biological mechanisms that guide cell fate to develop innovative therapeutics. Fates research and drug development focuses on modulating adult stem cell biology both in vivo and ex vivo to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Defense - Dept of (DOD) Natl Institutes of Health (NIH) Veterans Affairs - Dept of (VA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Secure federal assistance to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing, eyesight and bone fractures by using the fundamental biological mechanisms that guide cell fate to develop innovative therapeutics. Fates research and drug development focuses on modulating adult stem cell biology both in vivo and ex vivo to treat disease and improve health.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2009
PETRIZZO STRATEGIC GROUP, INC. filed a lobbying registration on Jan. 17, 2009 to represent Fate Therapeutics, Inc., effective Jan. 1, 2009.
Original Filing: 300125943.xml
Issue(s) they said they’d lobby about: Secure funding for for stem cell biology pogram to develop therapeutics based on modulating cell fate and enable a new drug discovery paradigm with the Company's proprietary induced pluripotent stem cell (iPSC) technology. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate